Guru Sonpavde, MD, of AdventHealth Cancer Institute, discusses several trials in the urologic oncology space while at ESMO Congress 2024, including AMBASSADOR, NIAGARA, CM901, and PRT3789.
Dr. Guru Sonpavde Discusses AMBASSADOR, NIAGARA, CM901, and PRT3789 at ESMO 2024
By Guru P. Sonpavde, MD - Last Updated: September 26, 2024Related Posts
Previous research has shown that BLC can provide improved detection rates, mainly for high-risk disease and invasive tumors.
Dr. Plimack details RETAIN, from early findings with neoadjuvant ddMVAC to the evolution of RETAIN-1 and RETAIN-2.
The panel elaborates on what excites them most about the future of UC research, highlighting promising advancements.
The panel considers the evolving role of ctDNA in guiding adjuvant therapy decisions, highlighting IMvigor011 and MODERN.
The panel shares the NIAGARA findings and results from RETAIN-2 on dose-dense MVAC for bladder preservation.
630 Madison Ave.
Manalapan, NJ 07726
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.